Antagonists in the 5-phenyl-benzomorphan series.
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D003061:Codeine / Q000494:pharmacology; D004361:Drug Tolerance; D006168:Guinea Pigs; D006207:Half-Life; D000882:Haplorhini; D006801:Humans; D007082:Ileum / Q000187:drug effects; D066298:In Vitro Techniques; D008614:Meperidine / Q000494:pharmacology; D051379:Mice; D008968:Molecular Conformation; D009019:Morphinans / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D009269:Nalorphine / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010423:Pentazocine / Q000494:pharmacology; D051381:Rats; D013329:Structure-Activity Relationship; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy; D019966:Substance-Related Disorders; D013623:Tail / Q000187:drug effects
D000700:Analgesics; D009019:Morphinans; D009292:Narcotic Antagonists; D008614:Meperidine; D010423:Pentazocine; D009269:Nalorphine; D003061:Codeine